AKT1 and hepatocellular carcinoma: CuB improves lipid, amino acid, and glucose metabolism disorders by regulating the AKT/mTORC1 signaling pathway, thereby inhibiting further formation and progression of HCC and opening up a new avenue for the clinical treatment of HCC by inhibiting the activities of lipids, amino acids, and glucose.